Lipp A, Lusardi G
University of Glamorgan, School of Care Sciences, Glyntaff, Pontypridd, UK.
Cochrane Database Syst Rev. 2006 Oct 18(4):CD005571. doi: 10.1002/14651858.CD005571.pub2.
Percutaneous endoscopic gastrostomies (PEG) maintain nutrition in the short or long term. A PEG is a feeding tube, placed surgically through the anterior abdominal wall, which delivers a liquid diet, or medication, via a clean or sterile delivery system. Those undergoing PEG placement are often vulnerable to infection because of age, compromised nutritional intake, immunosuppression and underlying disease processes such as malignancy and diabetes mellitus. The increasing incidence of methicillin-resistant Staphylococcus aureus (MRSA) contributes both an additional risk to the placement procedure, and also to the debate surrounding antibiotic prophylaxis for PEG placement. The aim of surgical antimicrobial prophylaxis is to establish a bactericidal concentration of an antimicrobial drug in the patients serum and tissues, via a brief course of an appropriate agent, by the time of PEG placement.
The review seeks to establish whether prophylactic use of systemic antimicrobials reduces the risk of peristomal infection in people undergoing placement of percutaneous endoscopic gastrostomies.
We searched the Cochrane Wounds Group Specialised Register (July 2006); The Cochrane Central Register of Controlled Trials (The Cochrane Library 2006, Issue 2); handsearched wound care journals relevant conference proceedings, and bibliographies of relevant publications identified by these strategies for further studies; and contacted manufacturers and distributors of PEG products.
Randomised controlled trials (RCTs) evaluating the use of prophylactic antimicrobials for PEG placement, with no restrictions for language, date or publication status.
Both authors performed data extraction and assessment of study quality. Meta-analysis was performed where appropriate.
We identified 10 eligible RCTs evaluating prophylactic antimicrobials in 1100 patients. All trials reported peristomal infection as an outcome, and a pooled analysis resulted in a statistically significant reduction in the incidence of peristomal infection with prophylactic antibiotics (pooled OR 0.31, 95% CI 0.22 to 0.44).
AUTHORS' CONCLUSIONS: Administration of systemic prophylactic antibiotics for PEG placement reduces peristomal infection.
经皮内镜下胃造口术(PEG)可在短期或长期维持营养。PEG是一种通过腹壁手术置入的饲管,通过清洁或无菌输送系统输送流质饮食或药物。接受PEG置入术的患者由于年龄、营养摄入不足、免疫抑制以及潜在疾病(如恶性肿瘤和糖尿病)等因素,往往易受感染。耐甲氧西林金黄色葡萄球菌(MRSA)发病率的上升,给PEG置入术增添了额外风险,也引发了关于PEG置入术预防性使用抗生素的争论。外科抗菌预防的目的是在PEG置入时,通过短期使用合适的抗菌药物,在患者血清和组织中建立抗菌药物的杀菌浓度。
本综述旨在确定全身预防性使用抗菌药物是否能降低接受经皮内镜下胃造口术患者的造口周围感染风险。
我们检索了Cochrane伤口组专业注册库(2006年7月);Cochrane对照试验中央注册库(Cochrane图书馆2006年第2期);手工检索伤口护理期刊、相关会议论文集以及通过这些策略识别出的相关出版物的参考文献以进行进一步研究;并联系了PEG产品的制造商和经销商。
评估预防性使用抗菌药物进行PEG置入术的随机对照试验(RCT),对语言、日期或发表状态无限制。
两位作者都进行了数据提取和研究质量评估。在适当情况下进行荟萃分析。
我们确定了10项符合条件的RCT,涉及1100例评估预防性抗菌药物的患者。所有试验均将造口周围感染作为一项结果报告,汇总分析显示预防性使用抗生素可使造口周围感染的发生率在统计学上显著降低(汇总比值比0.31,95%可信区间0,22至0.44)。
PEG置入术时使用全身预防性抗生素可降低造口周围感染。